Abdel Elmouchtari

Learn More
OBJECTIVE Nonadherence for first-episode schizophrenia is a major unsolved challenge. The long-acting injectable route is an appealing strategy, but there are concerns about acceptability. We report on acceptance and initial adherence outcomes with risperidone long-acting injection (RLAI) in first-episode schizophrenia patients. METHOD We conducted a(More)
BACKGROUND Because long-acting injectable (LAI) antipsychotics are largely reserved for persistently ill patients, little is known about the use of LAIs early in the course of illness for first-episode outpatients. METHOD A prospective, open-label, randomized controlled trial was conducted in which outpatients with first-episode DSM-IV schizophreniform(More)
  • 1